AVOLIO, CARLO
 Distribuzione geografica
Continente #
EU - Europa 2.546
NA - Nord America 2.380
AS - Asia 798
Continente sconosciuto - Info sul continente non disponibili 15
SA - Sud America 10
AF - Africa 7
OC - Oceania 6
Totale 5.762
Nazione #
US - Stati Uniti d'America 2.373
IE - Irlanda 880
CN - Cina 547
UA - Ucraina 480
SE - Svezia 387
IT - Italia 271
DE - Germania 146
FR - Francia 122
FI - Finlandia 111
SG - Singapore 90
IN - India 72
GB - Regno Unito 62
TR - Turchia 60
BE - Belgio 35
EU - Europa 15
RU - Federazione Russa 11
IR - Iran 9
BR - Brasile 8
NL - Olanda 8
AU - Australia 6
HK - Hong Kong 6
SC - Seychelles 6
AT - Austria 5
CA - Canada 5
CZ - Repubblica Ceca 4
ES - Italia 4
PK - Pakistan 4
PT - Portogallo 4
PL - Polonia 3
CH - Svizzera 2
HR - Croazia 2
KR - Corea 2
LU - Lussemburgo 2
RO - Romania 2
AM - Armenia 1
AR - Argentina 1
BD - Bangladesh 1
BZ - Belize 1
CL - Cile 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
JP - Giappone 1
KZ - Kazakistan 1
LT - Lituania 1
MD - Moldavia 1
MN - Mongolia 1
MY - Malesia 1
PR - Porto Rico 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
VN - Vietnam 1
Totale 5.762
Città #
Dublin 879
Chandler 403
Jacksonville 326
Nyköping 286
Dearborn 269
Nanjing 145
Princeton 90
Wilmington 88
Ashburn 68
Nanchang 65
Helsinki 62
Singapore 62
Beijing 61
Woodbridge 60
Ann Arbor 58
San Mateo 51
New York 45
Boardman 36
Brussels 35
Des Moines 33
Jiaxing 33
Shenyang 30
Foggia 29
Tianjin 25
Cedar Knolls 21
Changsha 21
Hebei 21
Kunming 19
Munich 19
Los Angeles 18
Rome 18
Guangzhou 15
Hangzhou 14
Zhengzhou 14
San Severo 12
Bari 11
Hilden 11
Ningbo 11
Norwalk 11
Redwood City 11
Taizhou 11
Jinan 10
Milan 10
Kocaeli 9
Pimonte 9
Seattle 9
Auburn Hills 8
Lanzhou 8
Falls Church 7
Naples 7
Hanover 6
Wuhan 6
Pune 5
Santeramo In Colle 5
Trento 5
Brindisi 4
Béligneux 4
Espoo 4
Fortaleza 4
Meda 4
Roanoke 4
Shanghai 4
Tehran 4
Terlizzi 4
Tsuen Wan 4
Canberra 3
Chicago 3
Council Bluffs 3
Fiorano Modenese 3
Frankfurt am Main 3
London 3
Manfredonia 3
Padova 3
Saint Petersburg 3
Salt Lake City 3
Shenzhen 3
Stevenage 3
Stockholm 3
São Paulo 3
Vicenza 3
Barletta 2
Bielefeld 2
Bologna 2
Brno 2
Buffalo 2
Changchun 2
Dallas 2
Dongyang 2
Florence 2
Geislingen an der Steige 2
Houston 2
Incheon 2
Karachi 2
Luxembourg 2
Marcon 2
Maslianico 2
Melbourne 2
Mountain View 2
Mumbai 2
Nantong 2
Totale 3.726
Nome #
Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register 137
Serial immunoprecipitation assays for interferon-(IFN)-beta antibodies in multiple sclerosis patients. 115
Serum Soluble Intercellular Adhesion Molecule-1 in MS: relation to clinical and Gd-MRI activity, and to rIFNβ-1b treatment. 105
Usefulness of a standardized method for collecting anamnestic data in multiple sclerosis (MS). 98
Defining the electroclinical phenotype and outcome of PCDH19‐related epilepsy: A multicenter study 95
CSF and serum soluble adhesion molecules in Multiple Sclerosis 94
Comparison of Clinical and demographic features between affected pairs of Italian Multiple Sclerosis Multiplex families; relation to Tumor Necrosis Factor genomic polymorphisms. 93
Espressione di LFA-1 su linfociti memoria CD4+CD45RO+ si sangue periferico nella Sclerosi Multipla remittente: effetti indotti dall’ IFN b-1a. 93
Design of a European multicenter study dedicated to the evaluation of the EDMUS system: EVALUED. 92
Intravenous lacosamide in seizure emergencies: Observations from a hospitalized in-patient adult population. 91
Changes of serum ICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. 90
Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. 89
Analisi fenotipica di linfociti T di pazienti con Sclerosi multipla (SM) nel sangue periferico ed in coltura con e senza aggiunta di mitogeni 89
Between-laboratory variability in oligoclonal IgG band numbering. 88
L’ esame del liquor (CSF) nella diagnosi di Sclerosi Multipla (SM) 88
European Validation of a Standardized Clinical Description of Multiple Sclerosis. 87
Intrathecal IgG synthesis in Multiple Sclerosis 87
Adhesion molecules and matrix metalloproteinases in MS: effects induced by Interferon beta. 86
Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a. 85
Analisi liquorale per la diagnosi ed il follow-up di malattie infiammatorie del SNC. 85
T regulatory cells are markers of disease activity in multiple sclerosis patients. 84
Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells 84
Disease duration, relapse rate and clinical course in Multiple Sclerosis. Relation to IgG production within the blood-brain barrier. 83
Epstein–Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role? 82
The epilepsy phenotype in adult patients with intellectual disability and pathogenic copy number variants 80
Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid (CSF) of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA Magnetic Resonance Imaging enhancement and CSF findings. 79
Wernicke's encephalopathy following reduced food intake due to depressive disorders. 79
Soluble Intercellular adhesion molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and the peripheral nervous system. 78
Effects of rIFNbeta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells. 78
Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. 77
Il ruolo dell’ esame del liquor 77
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. 77
Counting of peripheral extracellular vesicles in Multiple Sclerosis patients by an improved nanoplasmonic assay and dynamic light scattering 77
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in Multiple Sclerosis: relationships with different MRI measures of disease activity during IFN-beta-1a treatment. 76
Age-Related Disability in Multiple Sclerosis. 75
Sopluble Intercellular Adhesion Molecule-1 (sICAM-1) nel siero e liquor di pazienti con sclerosi multipla remittente clinicamente attiva: correlazioni con lesioni RMI che assumono gadolinio e con parametri liquorali 75
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. 74
P2X7 purinergic receptor on monocytes of patients with Multiple Sclerosis: effects of Glatiramer Acetate immune modulation 74
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. 73
Serum MMP-2 and MMP-9 are elevated in different Multiple Sclerosis subtypes. 73
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis 71
New Insights Into Immune Cell-Derived Extracellular Vesicles in Multiple Sclerosis. 71
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients. 70
LFA-1 expressing CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNbeta-1a. 69
Effetti antinfiammatori dell’ Interferone beta-1b ricombinante nella Sclerosi Multipla: studio longitudinale dei livelli sierici della forma solubile di Intercellular Adhesion Molecule-1 (sICAM-1) e dei subsets linfocitari 69
First-aid management of tonic-clonic seizures among healthcare personnel: A survey by the Apulian section of the Italian League Against Epilepsy 68
Interferon beta in relapsing / remitting multiple sclerosis: an independent postmarketing study in southern Italy. 67
Quantitation of intrathecal measles virus IgG antibody synthesis rate: Subacute sclerosing panencephalitis and multiple sclerosis. 66
Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients. 65
Immune and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients. 65
Usefulness of a standardised collection of disease events for clinical studies in Multiple Sclerosis. 64
Late-onset Leber hereditary optic neuropathy mimiking Susac’s syndrome 64
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 63
Glatiramer Acetate in Multiple Sclerosis: a review 63
Faciobrachial dystonic seizures expressed as epileptic spasms, followed by focal seizures in anti-LGI1 encephalitis: a video-polygraphic study. 61
Fisiopatologia della risposta immunitaria nel compartimento liquorale. XXXVII Congress of the Italian Neurological Society, Bari 14-18 October 2006. 60
An Italian multicentre study of perampanel in progressive myoclonus epilepsies 60
Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 60
How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study. 59
Prognostic indicators in pediatric clinically isolated syndrome. 57
Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease 57
Molecular Characterization of Peripheral Extracellular Vesicles in Clinically Isolated Syndrome: Preliminary Suggestions from a Pilot Study 56
From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases 56
Brivaracetam in Absence Status Epilepticus 54
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 54
IgG and IgM antibodies to the refolded MOG(1-125) extracellular domain in humans. 53
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion. 53
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. 53
Fluctuations of MS births and UV-light exposure. 52
The Italian multiple sclerosis register 51
Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production. 50
Pharmacological treatment of depression in Alzheimer's disease: A challenging task 50
Treatment with metformin in twelve patients with Lafora disease 49
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 46
Perceptive and Subjective Evaluation of Speech Disorders in Parkinson's Disease 46
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders 39
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 38
Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression (Q1 WoS) 37
Italian cohort of Lafora disease: Clinical features, disease evolution, and genotype-phenotype correlations 36
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 35
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. 35
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 33
The effect of quarantine due to Covid-19 pandemic on seizure frequency in 102 adult people with epilepsy from Apulia and Basilicata regions, Southern Italy 32
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 30
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives 29
THE PRESENTING SYMPTOMS OF LAFORA DISEASE: AN ELECTROCLINICAL AND GENETIC STUDY IN FIVE APULIAN (SOUTHERN ITALY) FAMILIES 28
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 28
Guillain-Barré syndrome as only manifestation of COVID-19 infection 28
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 27
Predictive factors of Status Epilepticus and its recurrence in patients with adult-onset seizures: A multicenter, long follow-up cohort study 25
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 25
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 25
Krebs cycle derivatives, dimethyl fumarate and itaconate, control metabolic reprogramming in inflammatory human microglia cell line 23
Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful 22
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 21
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 20
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries 18
Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer's disease 17
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 15
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 15
Totale 6.195
Categoria #
all - tutte 34.636
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.636


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020655 0 0 0 0 134 165 155 5 86 16 74 20
2020/2021652 78 3 75 29 91 28 93 46 92 110 3 4
2021/2022540 70 12 16 15 41 10 19 30 66 56 40 165
2022/20232.491 198 129 105 157 119 191 18 144 1.049 117 186 78
2023/2024389 65 55 23 24 43 69 32 17 4 8 18 31
2024/2025258 64 37 55 54 48 0 0 0 0 0 0 0
Totale 6.348